Successful therapeutic commercialization requires the demonstration of efficacy and safety of a drug during clinical trials, as well as the commercial feasibility of drug production with consistent quality. Mitigating risk in these three areas is the key strategy for pharmaceutical development success. One of the most effective ways of risk mitigation during therapeutic development is to perform drugability assessments of the molecule. Drugability assessment studies facilitate our understanding of biotherapeutics, predict clinical outcomes, and provide rationales for molecular optimization. Better understanding of biotherapeutic drugability ensures the manufacturability, safety, and efficacy in clinical development. Therefore, drugability assessment is the key for successful biotherapeutic commercialization. Here, we reviewed current literature, and summarized the major durability studies of biotherapeutics.
INTRODUCTION
Successful therapeutic commercialization requires the demonstration of efficacy and safety of a drug in clinical trials, as well as the commercially feasibility for production of the drug with consistent quality. From novel drug discovery to blockbuster commercialization, risk mitigation through drugability assessment is the key strategy for pharmaceutical development success 1 . The term drugability often refers to the accessibility, efficacy, and safety of a therapeutic molecule that meets clinical and commercial needs [2] [3] [4] [5] . Therefore, the drugability assessment of a molecule plays a significant role at an early stage of drug discovery. When it is performed properly, it can reduce the chance of expensive late-stage developmental failure 3, 4, 6, 7 . While many reviews have summarized the drugability of chemical therapeutics in literature 2, 5, [8] [9] [10] [11] [12] , few summarize biotherapeutic drugability assessment from current literature. Therefore, we reviewed thecurrent literature, and summarized the durability studies of biotherapeutics, particularly those studies that involve monoclonal antibodies (Mab).
Drugability of Biotherapeutics
When compared to traditional chemical therapeutics, biological drugs show promise in better safety, efficacy, specificity, and extended half-life. However, the molecular structural complexity of biotherapeutics underlies a variety of challenges and limitations. Examples of challenges and limitations are: long development time, inefficient penetration of cell membranes, high cost of manufacturing, unwanted immune response, and poor stability 13, 14 . During the early stage of discovery, the drugability of a biotherapeutic molecule should be extensively evaluated to reduce the chance of late-stage developmental failure. Figure 1 shows the primary goals to be achieved and major analytical techniques that are performed to determine drugability during early stages of drug discovery. Manufacturability, safety, and efficacy are the three major aspects of drugability that need to be addressed in the early stages of drug discovery.
Manufacturability
Biotherapeutics undergo multiple chemical and physical stresses during the manufacturing process. These stresses potentially lead to modifications of the target protein drug affecting its safety and effectiveness 15 . Manufacturing stress induced chemical modifications include oxidation, deamidation, peptides bond hydrolysis, etc.; and manufacturing stress induced physical modifications includes denaturation, precipitation, and aggregation, etc. Some of these induced modifications (e.g., aggregation, oxidation, glycosylation) can lead to heterogenicity and hence, significant adverse effects on the safety, efficacy, and pharmacokinetics/ pharmacodynamics (PK/PD) of the biotherapeutic drug 15, 16 Therefore, a quality assessment of stress induced modifications can provide necessary understanding of the physiochemical structures needed for lead candidates optimization.
Recent advances in proteomic techniques have enhanced understanding and prediction of protein modification resulting from bioprocesses 17, 18 , 19, 20 . These technologies provide diverse databases and analysis software to provide valuable information for controlling manufacturing stress induced protein modification 17, 18, [21] [22] [23] . Sequence-or structurebased bioinformatic prediction tools have been applied in recent studies 17, 18 . Table 1 .1 presents the summary of available computational tools for structural predictions. Biopharmaceutical companies use the In Silico platform to assess stress-induced modification tendencies in the molecular structure of biotherapeutics. By selecting the optimal candidates via the In Silico platform, biotherapeutic molecules can be optimized to eliminate potential structural liabilities during manufacturing 17, 24 . Optimized candidates are then selected for in vitro analysis including safety, yield, preformulation, and biological activity 17, 24 . 
Safety
Immunogenicity is one of the most common side effects for biotherapeutics. While the principal cause of the immune response is divided, immunogenicity leads to reduced drug efficacy, altered drug clearance, and shortened plasma half-life of the administered drug [25] [26] [27] [28] . Therefore, immunogenicity assessment is one of the most important principal safety evaluations for biotherapeutics in development 26, 28 .
Immunogenic response can be divided into T-cell dependent and T-cell independent responses. In T-cell independent immunogenic response, B cells bind to the therapeutic protein and respond by transiently producing IgM antibodies 29 .
In T-cell dependent immunogenic response, the complex interplay among antigen presenting cells, T cells, secreted cytokines, and B cells occur in respond to the administered proteins 30 . Thus, anti-drug antibodies (ADA) are usually generated by T-cell dependent immunogenic responses 25, 30 . Immunogenicity is one of the key risk attributes for clinical safety, so it is desirable to assess the potential immunogenic issues during the early discovery stages. A drug molecule should be redesigned if it is found to be highly immunogenic. One way to reduce the immunogenicity is by removing the T-cell epitopes of the biotherapeutic drug 24 . It is feasible to predict the immunogenicity of the T-cell epitopes based on the amino acid sequence from In Silico because their core residues are limited to 9-10 amino acids 30 .
There are a number of computational tools for T-cell epitope prediction and assessment for potential immunogenicity evaluations [30] [31] [32] . These In Silico predictions are usually followed by in vitro and ex vivo cell-based assays validation. Major histocompatibility complex/human leukocyte antigen (HLA/MHC) binding assays are common cell-based assays used to validate the In Silico predictions by measuring the affinity of predicted epitope to HLA in vitro 30, [33] [34] [35] . A series of T cells will then be used to further assess the immunogenicity, including cytokine response assays, proliferation assays, naïve human 30 . In vivo experiments with "humanized" animal models are also performed for immunogenicity testing of therapeutic candidates to further validate the findings in cell-based assays 36 . The data generated from the in vitro and in vivo validation assays provides an important assessment to the immunogenicity of the biotherapeutic protein to reduce clinical safety risks 30, 32 .
Typical screening assay strategies for immunogenicity of biopharmaceuticals are summarized in Table 2 . The data derived from these immunogenicity-based assessments can be used to prioritize candidates for development when multiple candidates are available. These assess ments can also be used to optimize biopharmaceutical candidates for cost-effective drug development and safety improvement via molecular redesign. Humanization is commonly used to significantly reduce immunogenicity [37] [38] [39] . Moreover, physicochemical modification and aggregation elimination of therapeutics can also be used to reduce immunogenicity 40 . Other immunogenicity reduction strategies such as PEGylation have been explored 41 . However, studies show that anti-PEG antibodies have been caused by PEGylated [42] [43] [44] [45] [46] . Nevertheless, immunogenicity reducing technologies are a key to mitigating the clinical safety risks of biotherapeutic developments.
Efficacy
Efficacy is frequently linked to the pharmacokinetics (PK) of a drug because of the direct relationship between efficacy and dosage. Special considerations are applied to biotherapeutics because of their complex structures [47] [48] [49] . The primary PK determinant of a biotherapeutic is their FcRnmediated recycling. However, other factors, such as glycosylation, and target mediated drug disposition (TMDD), and anti-drug antibody (ADA) response can also have tremendous influence on its PK 47 . Figure 3 illustrates the general structure of lgG1 and the factors that influence PK properties. PK data is important to reference during biotherapeutic structural optimization to achieve desirable exposure, safety, and efficacy profiles 47, [49] [50] [51] . The bioanalytical methods used for protein quantification during PK studies are mainly based on immunoassay methodologies. However, mass spectrometer based quantification techniques, including the bottom-up and top-down approach, are gaining popularity recently due to their advantages in development time, specificity, and throughput 52, 53 . In addition, fluorescent or radioactive labeled molecules are also frequently used to test absorption and distribution of Mab related therapeutics 54, 55 . The PK characteristics of biotherapeutics show differences from that of chemical therapeutics (Table 3) . PK data of biologics such as C max , Area Under Curve (AUC), half-life, volume of distribution, and clearance can help provide significant insight into their stability in blood, potential nonlinearity of PK, as well as target specific distribution assessment 47, 48, 53 . PK data from animal studies provides the basis of extrapolation for first-inhuman (FIH) dosage information in clinical studies. Linear PK, target-mediated drug disposition (TMDD), and physiology-based pharmacokinetic (PBPK) models are the most common FIH quantitative models used in order to show proper efficacy in clinical studies 56 .
Linear Pharmacokinetic (PK) Models -Protein biotherapeutics exhibit linear PK after saturation of target. PK data obtained in preclinical animal studies are typically extrapolated by simple mathematical models describing mono-exponential, bi-exponen tial, or multiexponential profiles observed in plasma or serum exposure. By using allomeric scaling techniques, intended dosage for human exposure predicted 57 .
Target-Mediated Drug Disposition (TMDD) Models -TMDD is applied when a significant fraction of a drug binds to its pharmacological target with high affinity such that this interaction influences the distribution and elimination of the drug 58 . A well-developed TMDD model can help predict drugrelated (e.g., drug elimination and distributional rate constants) and target-related (e.g., receptor expression) parameters, and estimate the in vivo receptor occupancy 56, 58 .
Physiology-based pharmacokinetic (PBPK) models -PBPK models describe physiological characteristics such as lymph flow, organ distribution, FcRn binding, and relationships with serum and tissue. In PBPK models, physiological parameters and the ADME data are integrated to represent a quantitative framework for mechanistic translation across species. This approach provides a starting point to evaluate the impact of drug-dependent properties and system-dependent properties on human PK profiles of biotherapeutics 56, [59] [60] [61] . Although it was first developed for chemical therapeutics, PBPK models have been extensively applied to biotherapeutics [59] [60] [61] .
Summary
Drugability of biotherapeutics is an integral concept in drug discovery. It involves the analyzation of a biological drugs' structural and physicochemical properties, biological activity, pharmokinetics and toxicity. Drugability assessment studies facilitate our understanding of biotherapeutics, predict clinical outcomes, and provide rationales for molecular optimization. Nevertheless, many studies, such as PK drivers of efficacy and toxicity, immunogenicity response, PK extrapolation to humans, and exposure-response relationships in patients etc, are currently in progress to gain better understanding of biotherapeutic drugability in order to ensure the manufacturability, safety, and efficacy in clinical development. With new advances in modern biotechnology, drugability assessments are the key for successful biotherapeutic commercialization. 
